Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2004

View Archived Issues

Small-molecule CFTR inhibitor for prevention of toxin-induced secretory diarrhea

In vivo antichlolesterolemic effects of fungal Beauveriolides I and III

Vitamin D synthesis reduced following burn injuries

Sildenafil in pulmonary arterial hypertension

Genmab highlights many accomplishments during 2003

Significant improvements found with ropinirole in restless legs syndrome

Draxis Health updates radiopharmaceuticals business

Novartis terminates PDI sales contract

Ark to float on London SE; four lead products in pipeline

Small-molecule EPO receptor modulators newly identified at Receptron

New anti-HCV agents described by researchers at K.U. Leuven and Gilead

BMS researchers claim novel agents for diabetes and obesity

Novel PDE4 inhibitors and their use described by Merck Frosst scientists

New PPARalpha/PPARgamma agonists in early development at Roche

Indian researchers prepare and test novel HMG-CoA reductase inhibitors

New NADPH oxidase inhibitors and their use in arthritis and Alzheimer's disease

Additional data on the safety and antiretroviral efficacy of enfuvirtide

First data on the safety and pharmacokinetics of the novel antiretroviral GW-873140

Strong antiviral effects reported for Reverset(TM) in treatment-naive HIV patients

Promising phase II results found for PCK-3145 in advanced prostate cancer

Discovery Partners signs new chemistry agreement with Pfizer

Rivex Pharma and Anika extend Canadian Orthovisc distribution agreement

Arilvax BLA temporarily withdrawn

Positive opinions for Promixin

Enrollment completed in REALITY stent trial

Australian Government grant supports advancement of PBT-2

Exelixis files IND for XL-647

Second phase III safety study of SPI-0211 confirms earlier positive results

NexMed licenses Femprox to CJ for Korea

Enrollment scheduled to conclude in pivotal MyVax trial

Clinical trial of ANA-971, oral prodrug of isatoribine

NovoSeven approved in Europe for factor VII deficiency and thrombasthenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...